Calcium pyrophosphate dihydrate crystals (CPPD crystals) (CPPD)

Calcium pyrophosphate dihydrate (CPPD) crystals are inorganic mineral precipitates that form in the fibrocartilage and hyaline cartilage of joints (StatPearls, 2023). These crystals are the primary pathological drivers of Calcium Pyrophosphate Deposition (CPPD) disease, which can manifest as acute inflammatory arthritis (pseudogout), chronic arthropathy, or asymptomatic chondrocalcinosis (Nature Reviews Rheumatology, 2016). At the cellular level, CPPD crystals act as danger-associated molecular patterns (DAMPs) that are phagocytosed by macrophages, subsequently triggering the assembly of the NLRP3 inflammasome (Annals of the Rheumatic Diseases, 2011). This process results in the release of pro-inflammatory cytokines, particularly interleukin-1 beta (IL-1β), which recruits neutrophils and propagates joint inflammation (Journal of Clinical Investigation, 2006). Because these crystals are metabolically stable and difficult to dissolve, therapeutic strategies focus on inhibiting the downstream inflammatory response rather than the crystals themselves (The Lancet Rheumatology, 2021). Standard treatments include colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids, while refractory cases may require biological inhibitors of the IL-1 pathway (Current Rheumatology Reports, 2021).

Other names

Calcium pyrophosphate dihydrateCPPD crystalsPseudogout crystalsChondrocalcinosis-associated crystalsPyrophosphate crystals

Pharmacological management focuses on inhibiting the inflammatory response triggered by the crystals, specifically through the inhibition of microtubule polymerization (colchicine), inhibition of cyclooxygenase enzymes (NSAIDs), and blockade of interleukin-1 receptors (anakinra).